Antreas Afantitis is the CEO of NovaMechanics Ltd. He received his B.S., M.Eng., M.S., and Ph.D. degrees in chemical engineering, process design and systems, computational mechanics, and computational and organic chemistry, respectively, from the School of Chemical Engineering (NTUA), Athens, Greece. Later, he pursued management studies toward an M.B.A. degree from the School of Electrical and Computer Engineering (NTUA), Athens, Greece. Afantitis has a strong scientific background in the fields of chemoinformatics, bioinformatics, and medicinal chemistry. The main field of the application of his research is drug discovery and property design and prediction. His scientific work has been published in 31 original research articles in international peer-reviewed journals. According to Web of Knowledge, his h-index is 16. Afantitis serves as a Reviewer for leading scientific journals (Journal of Chemical Information & Modeling, Journal of Molecular Graphics and Modeling, Chemometrics and Intelligent Laboratory Systems, European Journal of Medicinal Chemistry, Molecular Diversity, Chromatographia, Macromolecular Theory and Simulations, Molecules, Journal of Molecular Simulation, Expert Opinion On Drug Discovery, Arkivoc, Journal of Solution Chemistry, SAR and QSAR in Environmental Research, Letters in Drug Design & Discovery, Chemical Physics Letters, Journal of Computational Chemistry, Journal of Molecular Structure, Analytica Chimica Acta, Interdisciplinary Sciences: Computational Life Sciences, Bioorganic & Medicinal Chemistry Letters, Structural Chemistry, Chemosphere, BMC Bioinformatics, and Colloid and Polymer Science) and an evaluator of international competitive grants (Chilean Research Fund Council). His research mainly focuses on the development of tools that are able to derive high quality molecular descriptors and to efficiently manage huge amounts of available data in order to link structure-based drug design, chemoinformatics, and bioinformatics.
Biography Updated on 5 November 2013